肝/脾CT值、受控衰减参数（CAP）和磁共振质子密度脂肪分数（MRI-PDFF）在慢性乙型肝炎脂肪变性患者中的应用价值

鲁景楠; 李岩松; 温雅; 王雄慧; 屈兆宇; 李建龙; 张炜

doi:10.12449/JCH240109

肝/脾CT值、受控衰减参数（CAP）和磁共振质子密度脂肪分数（MRI-PDFF）在慢性乙型肝炎脂肪变性患者中的应用价值

DOI: 10.12449/JCH240109

1.
延安大学附属医院影像科，陕西延安 716000
2.
西安国际医学中心医院核医学科，西安 710100

基金项目:

延安市科学技术研究发展计划项目 (2018KS-11)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：鲁景楠、张炜对研究的思路或设计有关键贡献；李岩松、温雅、王雄慧、屈兆宇参与了研究数据的获取分析解释过程；鲁景楠、张炜、李建龙参与起草及修改文章关键内容。

详细信息

通信作者:
张炜， 304180598@qq.com （ORCID： 0009-0009-2951-1115）

计量
- 文章访问数: 504
- HTML全文浏览量: 285
- PDF下载量: 65
- 被引次数: 0
出版历程
- 收稿日期: 2023-04-20
- 录用日期: 2023-05-06
- 出版日期: 2024-01-23

Application value of liver/spleen CT value， controlled attenuation parameter， and magnetic resonance imaging-proton density fat fraction in chronic hepatitis B patients with hepatic steatosis

1.
Department of Medical Imaging，Affiliated Hospital of Yan’an University，Yan’an，Shaanxi 716000，China
2.
Department of Nuclear Medicine，Xi’an International Medical Center Hospital，Xi’an 710100，China

Research funding:

Science and Technology Research and Development Project of Yan’an (2018KS-11)

More Information

Corresponding author: ZHANG Wei， 304180598@qq.com （ORCID： 0009-0009-2951-1115）

摘要

摘要: 目的探讨肝/脾CT值（CT_L/S）、受控衰减参数（CAP）和磁共振质子密度脂肪分数（MRI-PDFF）在慢性乙型肝炎（CHB）肝脂肪变性患者中的应用价值。方法回顾性收集2018年10月—2022年12月在延安大学附属医院行肝脏CT、CAP和MRI-PDFF检查的213例CHB患者的临床资料。根据MRI-PDFF结果，将213例患者分为单纯CHB组（MRI-PDFF<5%，n=111）和CHB合并脂肪变性组（MRI-PDFF≥5%，n=102）；其中轻度脂肪变性69例，中度至重度脂肪变性33例。符合正态分布的计量资料组间比较采用成组t检验；不符合正态分布的计量资料组间比较采用Mann-Whitney U检验。绘制Bland-Altman图，评价两位医师测量MRI-PDFF的一致性。采用Spearman相关系数分析CT_L/S和MRI-PDFF、CAP和MRI-PDFF的相关性。通过分析受试者工作特征曲线（ROC曲线），计算曲线下面积（AUC），评估CT_L/S和CAP对不同程度脂肪变性的诊断价值，并使用DeLong检验比较两种影像诊断方法的AUC。结果 MRI-PDFF在CHB患者中具有较高的可重复性及稳定性，CT_L/S和MRI-PDFF之间呈显著负相关（r=-0.800，P<0.001），CAP与MRI-PDFF之间呈显著正相关（r=0.692，P<0.001）。CT_L/S和CAP诊断CHB肝脂肪变性均有较高的准确度（AUC分别为0.951、0.902），且CT_L/S优于CAP（P<0.05）。在检测轻度和中重度脂肪变性时，CT_L/S的AUC分别为0.921和0.895，CAP的AUC分别为0.859和0.825。结论 MRI-PDFF技术在CHB患者中具有较高的可重复性及稳定性，CT_L/S和CAP对不同程度的CHB肝脂肪变性均具有较高的诊断价值。
- 乙型肝炎，慢性 /
- 脂肪肝 /
- 诊断
Abstract: Objective To investigate the application value of liver/spleen CT value （CT_L/S）， controlled attenuation parameter （CAP）， and magnetic resonance imaging-proton density fat fraction （MRI-PDFF） in chronic hepatitis B （CHB） patients with hepatic steatosis. Methods A retrospective analysis was performed for the clinical data of 213 CHB patients who underwent liver CT， CAP， and MRI-PDFF examinations in Affiliated Hospital of Yan’an University from October 2018 to December 2022. According to MRI-PDFF， the 213 patients were divided into CHB group with 111 patients （MRI-PDFF<5%） and CHB+hepatic steatosis group with 102 patients （MRI-PDFF≥5%）， among whom there were 69 patients with mild hepatic steatosis and 33 patients with moderate to severe hepatic steatosis. The independent-samples t test was used for comparison of normally distributed continuous data between groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The Bland-Altman plot was used to evaluate the consistency in MRI-PDFF measurement between two physicians. The Spearman’s correlation coefficient was used to analyze the correlation between CT_L/S and MRI-PDFF and between CAP and MRI-PDFF. The receiver operating characteristic （ROC） curve was plotted and the area under the ROC curve （AUC） was calculated to investigate the value of CT_L/S and CAP in the diagnosis of different degrees of hepatic steatosis， and the DeLong test was used to compare the AUCs of the two radiological examinations. Results MRI-PDFF had relatively high repeatability and stability in CHB patients. There is a significant negative correlation between CT_L/S and MRI-PDFF （r=-0.800， P<0.001） and a significant positive correlation between CAP and MRI-PDFF （r=0.692， P<0.001）. Both CT_L/S and CAP had a relatively high accuracy in the diagnosis of hepatic steatosis in CHB patients， with an AUC of 0.951 and 0.902， respectively， and CT_L/S had a better accuracy than CAP （P<0.05）. In the diagnosis of mild and moderate-to-severe hepatic steatosis， CT_L/S had an AUC of 0.921 and 0.895， respectively， and CAP had an AUC of 0.859 and 0.825， respectively， suggesting that CT_L/S had a slightly higher diagnostic efficiency than CAP. Conclusion MRI-PDFF has high repeatability and stability in CHB patients， and CT_L/S and CAP have a high diagnostic value for different degrees of hepatic steatosis in CHB patients.
- Hepatitis B， Chronic /
- Fatty Liver /
- Diagnosis

HTML全文

图 1 CT_L/S测量示例图

注： a，47岁男性，CHB合并轻度脂肪变性，CT_L/S为0.85；b，44岁男性，CHB合并重度脂肪变性，CT_L/S为0.43。

Figure 1. Sample figure of CT_L/S measurements

下载: 全尺寸图片幻灯片

图 2 MRI-PDFF测量示例图

注： a，57岁女性，CHB合并轻度脂肪变性，MRI-PDFF为6.82%；b，46岁男性，CHB合并重度脂肪变性，MRI-PDFF为17.04%。

Figure 2. Sample figure of MRI-PDFF measurements

下载: 全尺寸图片幻灯片

图 3 测量者间的一致性分析（Bland-Altman图）

Figure 3. Interobserver agreement analysis （Bland-Altman plot）

下载: 全尺寸图片幻灯片

图 4 MRI-PDFF与CT_L/S、CAP的相关性分析

Figure 4. Correlation analysis of MRI-PDFF with CT_L/S and CAP

下载: 全尺寸图片幻灯片

图 5 CT_L/S和CAP检测不同程度脂肪变性的ROC曲线

注： a，有无脂肪变性；b，轻度脂肪变性；c，中重度脂肪变性。

Figure 5. ROC curves of CT_L/S and CAP to detect different degrees of steatosis

下载: 全尺寸图片幻灯片

表 1 单纯CHB组和CHB合并脂肪变性组的临床特征、影像学特征比较

Table 1. Comparison of clinical and imaging features between simple CHB group and CHB with steatosis group

项目	单纯CHB组（n=111）	CHB合并脂肪变性组（n=102）	统计值	P值
性别［例（%）］			χ²=6.191	0.013
男	66（59）	77（75）
女	45（41）	25（25）
年龄（岁）	50.00±11.17	47.00±9.79	t=0.146	0.084
BMI（kg/m²）	23.67（21.86～25.26）	26.38（23.88～28.40）	Z=-5.887	P<0.001
CAP（dB/m）	216.00±42.21	291.50±42.91	t=-14.236	P<0.001
CT_L/S	1.27（1.20～1.34）	0.97（0.83～1.04）	Z=-11.368	P<0.001
MRI-PDFF	2.45%（2.19%～2.80%）	7.55%（6.12%～11.85%）	Z=-12.598	P<0.001

下载: 导出CSV

表 2 CT_L/S和CAP对慢性乙型肝炎不同程度脂肪变性的诊断效能

Table 2. Diagnostic efficacy of CT_L/S and CAP for different degrees of steatosis in chronic hepatitis B

项目	无脂肪变性 vs 脂肪变性	无脂肪变性 vs 轻度脂肪变性	轻度脂肪变性 vs 中重度脂肪变性
CT_L/S
最佳截断值	1.09	1.17	0.97
AUC	0.951	0.921	0.895
灵敏度（%）	86.3	91.2	93.9
特异度（%）	93.7	83.9	71.0
阳性预测值（%）	92.6	77.5	60.8
阴性预测值（%）	88.1	94.0	96.1
CAP
最佳截断值	251.5	251.5	285.5
AUC	0.902^1）	0.859	0.825
灵敏度（%）	89.2	83.8	90.9
特异度（%）	77.5	76.8	63.8
阳性预测值（%）	78.4	68.7	54.5
阴性预测值（%）	88.7	88.7	93.6
注：与CT_L/S比较，1）P<0.05。

下载: 导出CSV

参考文献(21)

[1]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3( 6): 383- 403. DOI: 10.1016/S2468-1253(18)30056-6.
[2]	ZHOU WW, HUANG J, PAN FM. Research progress in epidemiological characteristics and therapeutic drugs of chronic hepatitis B[J]. J Changchun Univ Chin Med, 2022, 38( 12): 1420- 1424. DOI: 10.13463/j.cnki.cczyy.2022.12.028. 周薇薇, 黄俊, 潘发明. 慢性乙型肝炎流行病学特点和治疗药物研究进展[J]. 长春中医药大学学报, 2022, 38( 12): 1420- 1424. DOI: 10.13463/j.cnki.cczyy.2022.12.028.
[3]	RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77( 5): 1797- 1835. DOI: 10.1097/HEP.0000000000000323.
[4]	LEE YB, HA Y, CHON YE, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Clin Mol Hepatol, 2019, 25( 1): 52- 64. DOI: 10.3350/cmh.2018.0040.
[5]	SHIHA G, IBRAHIM A, HELMY A, et al. Asian-Pacific Association for the Study of the Liver(APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update[J]. Hepatol Int, 2017, 11( 1): 1- 30. DOI: 10.1007/s12072-016-9760-3.
[6]	ROGIER J, ROULLET S, CORNÉLIS F, et al. Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio[J]. Liver Transpl, 2015, 21( 5): 690- 695. DOI: 10.1002/lt.24105.
[7]	FERRAIOLI G. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter(Echosens)[J]. J Med Ultrason(2001), 2021, 48( 4): 489- 495. DOI: 10.1007/s10396-021-01106-1.
[8]	Committee of Hepatology, Chinese Research Hospital Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, et al. Expert recommendations on standardized diagnosis and treatment for fatty liver disease(2019 revised edition)[J]. J Clin Hepatol, 2019, 35( 11): 2426- 2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007. 中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 等. 脂肪性肝病诊疗规范化的专家建议(2019年修订版)[J]. 临床肝胆病杂志, 2019, 35( 11): 2426- 2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007.
[9]	TAMAKI N, AJMERA V, LOOMBA R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD[J]. Nat Rev Endocrinol, 2022, 18( 1): 55- 66. DOI: 10.1038/s41574-021-00584-0.
[10]	DULAI PS, SIRLIN CB, LOOMBA R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice[J]. J Hepatol, 2016, 65( 5): 1006- 1016. DOI: 10.1016/j.jhep.2016.06.005.
[11]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[12]	YE J, WU Y, LI F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819879047. DOI: 10.1177/1756284819879047.
[13]	YANG M, WEI L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia[J]. Liver Int, 2022, 42( 9): 1981- 1990. DOI: 10.1111/liv.15252.
[14]	CASTERA L, FRIEDRICH-RUST M, LOOMBA R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156( 5): 1264- 1281.e4. DOI: 10.1053/j.gastro.2018.12.036.
[15]	PARK CC, NGUYEN P, HERNANDEZ C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 3): 598- 607.e2. DOI: 10.1053/j.gastro.2016.10.026.
[16]	LEE SS, PARK SH. Radiologic evaluation of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20( 23): 7392- 7402. DOI: 10.3748/wjg.v20.i23.7392.
[17]	ZHONG L, CHEN JJ, CHEN J, et al. Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy[J]. J Dig Dis, 2009, 10( 4): 315- 320. DOI: 10.1111/j.1751-2980.2009.00402.x.
[18]	CHEN S, HUANG ZH. Advances in quantitative imaging evaluation of non-alcoholic fatty liver disease[J]. J New Clin Medicine, 2018, 11( 12): 1283- 1286. DOI: 10.3969/j.issn.1674-3806.2018.12.32. 陈松, 黄泽和. 非酒精性脂肪肝病的影像学定量评估研究进展[J]. 中国临床新医学, 2018, 11( 12): 1283- 1286. DOI: 10.3969/j.issn.1674-3806.2018.12.32.
[19]	KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66( 5): 1022- 1030. DOI: 10.1016/j.jhep.2016.12.022.
[20]	NOGAMI A, YONEDA M, IWAKI M, et al. Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future[J]. Clin Mol Hepatol, 2023, 29( Suppl): S123- S135. DOI: 10.3350/cmh.2022.0357.
[21]	MA YN, LIU JC. Research progress in the noninvasive quantitative diagnosis of hepatic steatosis using controlled attenuation parameters[J]. Chin J Gastroenterol Hepatol, 2020, 29( 11): 1309- 1312. DOI: 10.3969/j.issn.1006-5709.2020.11.023. 马亚楠, 刘近春. 受控衰减参数无创定量诊断肝脂肪变性的研究进展[J]. 胃肠病学和肝病学杂志, 2020, 29( 11): 1309- 1312. DOI: 10.3969/j.issn.1006-5709.2020.11.023.